Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
-
-
-
?
(5Z,13E)-(15S)-9alpha,11beta,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
-
-
-
?
9,10-phenanthrenequinone + NADPH
? + NADP+
-
-
-
?
androst-4-ene-3,17-dione + NADPH
? + NADP+
-
-
-
?
prostaglandin D2 + NADP+
9alpha,11beta-prostaglandin F2 + NADPH
-
-
-
?
prostaglandin D2 + NADPH + H+
9alpha,11beta-prostaglandin F2 + NADP+
-
-
-
?
prostaglandin D2 + NADPH + H+
9alpha,11beta-prostaglandin F2alpha + NADP+
-
-
-
r
prostaglandin D2 + NADPH + H+
prostaglandin 9alpha,11beta-F2 + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
aldo-keto reductase has prostaglandin F2alpha synthase activity. AKR1B1 is a more efficient prostaglandin F2alpha synthase than AKR1C3
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
prostamide D2 + NADPH + H+
9alpha,11beta-prostamide F2 + NADP+
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH
(5Z,13E)-(15S)-9alpha,11beta,15-trihydroxyprosta-5,13-dienoate + NADP+
-
-
-
-
?
4-nitrobenzaldehyde + NADPH
4-nitrobenzyl alcohol + NADP+
-
-
-
-
?
4-nitrobenzaldehyde + NADPH + H+
(4-nitrophenyl)methanol + NADP+
-
-
-
?
5beta-androstane-3,17-dione + NADPH
5beta-androstan-3alpha-ol-17-one + NADP+
-
-
-
-
r
9,10-phenanthrenequinone + NADPH
?
9,10-phenanthrenequinone + NADPH + H+
?
-
-
-
?
prostaglandin D2 + NADPH + H+
9-alpha,11-beta-prostaglandin F2 + NADP+
-
-
-
-
?
prostaglandin D2 + NADPH + H+
9alpha,11alpha-prostaglandin F2alpha + NADP+
-
reaction via formation of the endoperoxide ethanolamide intermediate prostaglandin H2
-
-
?
prostaglandin D2 + NADPH + H+
9alpha,11beta-prostaglandin F2 + NADP+
-
-
-
?
prostaglandin D2 + NADPH + H+
9alpha,11beta-prostaglandin F2alphabeta + NADP+
-
-
-
?
prostaglandin D2 + NADPH + H+
prostaglandin 9alpha,11beta-F2 + NADP+
prostaglandin D2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
?
prostaglandin D2 ethanolamide + NADPH
prostaglandin 9alpha,11beta-F2 ethanolamide + NADP+
i.e. prostamide D2
i.e. 91lpha,11beta-prostamide F2
-
?
prostaglandin H2 + NADP+
prostaglandin F2alpha + NADPH + H+
prostaglandin H2 + NADPH + H+
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
prostaglandin H2 + NADPH + H+
9alpha,11alpha-prostaglandin F2alpha + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
9alpha,11beta-prostaglandin F2 + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin 9alpha,11beta-F2 + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin D2 + NADP+
-
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
prostamide H2 + NADPH + H+
prostamide F2alpha + NADP+
-
about 70% of prostamide H2 is converted to prostamide F2alpha after 2 min at 37°C
-
-
?
additional information
?
-
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
-
-
-
?
9,10-phenanthrenequinone + NADPH
?
-
-
-
-
?
9,10-phenanthrenequinone + NADPH
?
-
i.e. PQ
-
-
?
prostaglandin D2 + NADPH + H+
prostaglandin 9alpha,11beta-F2 + NADP+
-
-
-
?
prostaglandin D2 + NADPH + H+
prostaglandin 9alpha,11beta-F2 + NADP+
-
-
product is involved in bronchial, vascular, and arterial smooth muscle contraction, product inhibits platelet aggregation and activates urinary excretion, i.e. 11-epi PGF2alpha
-
?
prostaglandin H2 + NADP+
prostaglandin F2alpha + NADPH + H+
-
-
-
?
prostaglandin H2 + NADP+
prostaglandin F2alpha + NADPH + H+
-
-
-
-
?
prostaglandin H2 + NADPH + H+
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
-
-
-
-
?
prostaglandin H2 + NADPH + H+
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
aldo-keto reductase has prostaglandin F2alpha synthase activity. AKR1B1 is a more efficient prostaglandin F2alpha synthase than AKR1C3
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
enzyme also shows PGH2 9-,11-endoperoxide reductase activity
-
-
?
additional information
?
-
acive site structure, enzyme also shows 3alpha-hydroxysteroid dehydrogenase type II activity
-
-
?
additional information
?
-
Y55 and H117 are involved in catalysis, enzyme also shows 3alpha-hydroxysteroid dehydrogenase type II activity
-
-
?
additional information
?
-
-
Y55 and H117 are involved in catalysis, enzyme also shows 3alpha-hydroxysteroid dehydrogenase type II activity
-
-
?
additional information
?
-
-
PGFS does not catalyze the reduction of prostaglandin E2
-
-
?
additional information
?
-
PGFS does not catalyze the reduction of prostaglandin E2
-
-
?
additional information
?
-
AKR1C3 is overexpressed in keloids and mediates the conversion of PGD2 to 9alpha,11beta-PGF2 in keloid and normal fibroblasts
-
-
?
additional information
?
-
-
the cytosolic enzyme synergistically interacts with cyclooxygenase 1 and 2, coupling, isozyme PGFS-I interacts predominantly with cyclooxygenase 2, i.e. COX-2
-
-
?
additional information
?
-
-
substrate and product detection by liquid chromatographic-electrospray ionization-mass spectrometry
-
-
?
additional information
?
-
substrate and product detection by liquid chromatographic-electrospray ionization-mass spectrometry
-
-
?
additional information
?
-
-
the enzyme has dual activity as PGD2 11-ketoreductase and PGH2 9,11-endoperoxide reductase
-
-
?
additional information
?
-
the enzyme has dual activity as PGD2 11-ketoreductase and PGH2 9,11-endoperoxide reductase
-
-
?
additional information
?
-
in the absence of NADPH or NADP+, enzyme catalyzes the isomerization of prostaglandin H2 to prostaglandin D2 with a Km value of 0.023 mM. This activity of AKR1B1 increases with increasing pH, with an optimum of pH 8.5. Residue His110 acts as a base in concert with Asp43 and Lys77 and as an acid to generate PGD2 and PGF2a in the absence of NADPH or NADP+ and in the presence of NADPH, respectively
-
-
?
additional information
?
-
-
in the absence of NADPH or NADP+, enzyme catalyzes the isomerization of prostaglandin H2 to prostaglandin D2 with a Km value of 0.023 mM. This activity of AKR1B1 increases with increasing pH, with an optimum of pH 8.5. Residue His110 acts as a base in concert with Asp43 and Lys77 and as an acid to generate PGD2 and PGF2a in the absence of NADPH or NADP+ and in the presence of NADPH, respectively
-
-
?
additional information
?
-
PGFS activity of the recombinant proteins is evaluated using an assay based on in situ generation of the precursor of prostaglandin PGH2 biosynthesis. PGF2alpha is measured by ELISA. Comparisons of PGFS activity of recombinant bovine and human endometrial AKRs, overview
-
-
?
additional information
?
-
-
PGFS activity of the recombinant proteins is evaluated using an assay based on in situ generation of the precursor of prostaglandin PGH2 biosynthesis. PGF2alpha is measured by ELISA. Comparisons of PGFS activity of recombinant bovine and human endometrial AKRs, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
-
-
-
?
(5Z,13E)-(15S)-9alpha,11beta,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
-
-
-
?
prostaglandin D2 + NADP+
9alpha,11beta-prostaglandin F2 + NADPH
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
prostaglandin D2 + NADPH + H+
9-alpha,11-beta-prostaglandin F2 + NADP+
-
-
-
-
?
prostaglandin D2 + NADPH + H+
9alpha,11beta-prostaglandin F2alphabeta + NADP+
-
-
-
?
prostaglandin D2 + NADPH + H+
prostaglandin 9alpha,11beta-F2 + NADP+
-
-
product is involved in bronchial, vascular, and arterial smooth muscle contraction, product inhibits platelet aggregation and activates urinary excretion
-
?
prostaglandin H2 + NADP+
prostaglandin F2alpha + NADPH + H+
prostaglandin H2 + NADPH + H+
9alpha,11alpha-prostaglandin F2alpha + NADP+
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin D2 + NADP+
-
-
-
-
?
prostaglandin H2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
-
?
additional information
?
-
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate + NADP+
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH + H+
-
-
-
?
prostaglandin H2 + NADP+
prostaglandin F2alpha + NADPH + H+
-
-
-
?
prostaglandin H2 + NADP+
prostaglandin F2alpha + NADPH + H+
-
-
-
-
?
additional information
?
-
AKR1C3 is overexpressed in keloids and mediates the conversion of PGD2 to 9alpha,11beta-PGF2 in keloid and normal fibroblasts
-
-
?
additional information
?
-
-
the cytosolic enzyme synergistically interacts with cyclooxygenase 1 and 2, coupling, isozyme PGFS-I interacts predominantly with cyclooxygenase 2, i.e. COX-2
-
-
?
additional information
?
-
-
the enzyme has dual activity as PGD2 11-ketoreductase and PGH2 9,11-endoperoxide reductase
-
-
?
additional information
?
-
the enzyme has dual activity as PGD2 11-ketoreductase and PGH2 9,11-endoperoxide reductase
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
bimatoprost
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
ONO1370
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
ONO1349
(5Z)-7-[(1S,4S,5S,6R)-2-methyl-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
ONO1373
1-(4-aminobenzyl)-5-methoxy-2-methylindoleacetic acid
-
15-deoxy-DELTA12,14-prostaglandin J2
15d-PGJ2, the enzyme inhibitor attenuates proliferation, inhibits collagen gel contraction and induces activation of the apoptotic marker, caspase-3, in CRL1762 keloid fibroblasts
2-(1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl)-N-((trifluoromethyl)sulfonyl)acetamide
257fold selectivity for isoform AKR1C3 over isoform AKR1C2
3-(1-(4-chlorobenzoyl)-3-ethyl-5-methoxy-1H-indol-2-yl)-propanoic acid
540fold selectivity for isoform AKR1C3 over isoform AKR1C2
3-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-propanoic acid
257fold selectivity for isoform AKR1C3 over isoform AKR1C2
4-carboxy-2',4'-dinitrodiphenylamine
-
4-carboxy-2-aminodiphenylamine
-
4-chloro-N-(4-tolyl)-anthranilic acid
-
4-chloro-N-phenylanthranilic acid
-
4-nitro-N-phenylanthranilic acid
-
5-methyl-N-phenylanthranilic acid
-
9,10-phenanthrenequinone
the prostaglandin D2 11-ketoreductase activity of PGFS is competitively inhibited by 9,10-phenanthrenequinone
acetate
occupies the oxyanion hole of the active site, 2 complex structures
Flufenamic acid
nonsteroidal anti-inflammatory drug, binds to both the active site and the beta-hairpin loop at the opposite end of the central beta-barrel, complex structure
indomethacin methyl ester
specific inhibition of isoform AKR1C3 versus AKR1C1 and AKR1C3
N-(4-chlorobenzoyl)-melatonin
rutin
binding structure at the substrate binding site
tert-butyl hydroperoxide
-
(Z)-7-[(1R,4S,5S,6R)-((E)-6-oct-1-enyl)-2-aza-bicyclo[2.2.1]hept-5-yl]-hept-5-enoic acid
inhibition of PGH2 9,11-endoperoxide reductase activity, slight inhibition of prostamide D2 11-ketoreductase and PGD2 11-ketoreductase activity
(Z)-7-[(1R,4S,5S,6R)-2-methyl-6-((E)-oct-1-enyl)-2-aza-bicyclo[2.2.1]hept-5-yl]-hept-5-enoic acid
inhibition of PGH2 9,11-endoperoxide reductase activity, slight inhibition of prostamide D2 11-ketoreductase and PGD2 11-ketoreductase activity, competitive, binds to the active site
(Z)-7-[(1R,4S,5S,6R)-6-((E)-(S)-3-hydroxy-oct-1-enyl)-2-aza-bicyclo[2.2.1]hept-5-yl]-hept-5-enoic acid
inhibition of PGH2 9,11-endoperoxide reductase activity, slight inhibition of prostamide D2 11-ketoreductase and PGD2 11-ketoreductase activity
4-carboxy-2',4'-dinitrodiphenylamine
-
4-carboxy-2-aminodiphenylamine
-
4-chloro-N-(4-tolyl)-anthranilic acid
-
4-chloro-N-phenylanthranilic acid
-
4-nitro-N-phenylanthranilic acid
-
5-methyl-N-phenylanthranilic acid
-
9,10-phenanthrenequinone
-
bimatoprost
ethyl amide analogue of 17-phenyl-trinor PGF2alpha, inhibits all enzyme activities noncompetitively at low concentration, binds to a site different from the active site
ponalrestat
specific inhibitor developed to block AKR1B1 activity. Application reduces prostaglandin F2alpha production in response to interleukin IL-1beta in both cultured endometrial cells and endometrial explants
bimatoprost
potent inhibitor
bimatoprost
inhibits the prostaglandin D2 11-ketoreductase activity as well as the prostaglandin H2 9,11-endoperoxide reductase activity of PGFS
flurbiprofen
-
Ibuprofen
-
indomethacin
-
indomethacin
nonsteroidal anti-inflammatory drug, 1 molecule binds to the active site, complex structure
indomethacin
specific inhibition of isoform AKR1C3 versus AKR1C1 and AKR1C3
indomethacin
inhibits AKR1C3, but does not inhibit highly related AKR1C1 or AKR1C2
Meclofenamic acid
-
N-(4-chlorobenzoyl)-melatonin
specific inhibition of isoform AKR1C3 versus AKR1C1 and AKR1C3, not inhibitory to cyclooxygenases. Uncompetitive versus 9,10-phenynthrenequinone, competitive versus DELTA4-andostene-3,17-dione
N-(4-chlorobenzoyl)-melatonin
exhibits uncompetitive inhibition patterns for the reduction of 9,10-phenanthrenequinone but competitive inhibition patterns for the reduction of androstenedione by AKR1C3
naproxen
-
sulindac
-
Tolrestat
-
Zomepirac
-
Tolrestat
-
Tolrestat
inhibition of all 3 enzyme activities, most effective inhibiting the PGD2 11-ketoreductase activity
additional information
-
AKR1C3 is potently inhibited by non-steroidal anti-inflammatory drugs, which are protective against breast cancer
-
additional information
AKR1C3 is potently inhibited by non-steroidal anti-inflammatory drugs, which are protective against breast cancer
-
additional information
combination of indomethacin with tert-butyl hydroperoxide significantly inhibits the growth of radiation-resistant AKR1C3-over cells
-
additional information
heat treatment of AKR1B1 at 100°C for 5 min completely inactivates the prostaglandin F2alpha synthase activity, which is strictly dependent on the presence of NADPH
-
additional information
heat treatment of AKR1B1 at 100°C for 5 min completely inactivates the prostaglandin F2alpha synthase activity, which is strictly dependent on the presence of NADPH
-
additional information
-
heat treatment of AKR1B1 at 100°C for 5 min completely inactivates the prostaglandin F2alpha synthase activity, which is strictly dependent on the presence of NADPH
-
additional information
inhibitors such as alrestatin, ponalrestat, and EBPC exhibit distinct and characteristic inhibition of prostaglandin F2alpha production in different cell models
-
additional information
-
inhibitors such as alrestatin, ponalrestat, and EBPC exhibit distinct and characteristic inhibition of prostaglandin F2alpha production in different cell models
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Asthma
cDNA cloning, expression and characterization of human prostaglandin F synthase.
Asthma
Physiology and pharmacology of prostaglandins.
Callosities
Whole-cell response characteristics of ciliated and microvillous olfactory receptor neurons to amino acids, pheromone candidates and urine in rainbow trout.
Carcinogenesis
Adrenal tumorigenesis targeted by the corticotropin-regulated promoter of the aldo-keto reductase AKR1B7 gene in transgenic mice.
Carcinogenesis
Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma.
Carcinoma
Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma.
Carcinoma
Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs.
Carcinoma, Renal Cell
Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma.
Carcinoma, Squamous Cell
Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs.
Cardiomegaly
Identification of a novel aldose reductase-like gene upregulated in the failing heart of cardiomyopathic hamster.
Dental Caries
CovR and VicRKX regulate transcription of the collagen binding protein Cnm of Streptococcus mutans.
Diabetes Complications
A delayed-early gene activated by fibroblast growth factor-1 encodes a protein related to aldose reductase.
Diabetes Complications
The Human Aldose Reductase AKR1B1 Qualifies as the Primary Prostaglandin F Synthase in the Endometrium.
Diabetes Mellitus
Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis.
Dystocia
Do uterine PTGS2, PGFS, and PTGFR expression play a role in canine uterine inertia?
Endocarditis
CovR and VicRKX regulate transcription of the collagen binding protein Cnm of Streptococcus mutans.
Fatty Liver
Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis.
Hematologic Neoplasms
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
Herpes Simplex
Primary graft failure caused by herpes simplex virus type 1.
Herpes Zoster
Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis.
Hypertriglyceridemia
Role of the pregnane X receptor in binge ethanol-induced steatosis and hepatotoxicity.
Infections
CovR and VicRKX regulate transcription of the collagen binding protein Cnm of Streptococcus mutans.
Liver Diseases
Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis.
Lung Diseases
Clinical evaluation of main urinary metabolite of PGFs in chronic lung diseases.
Neoplasms
ACTH and PRL sensitivity of highly differentiated cell lines obtained by adrenocortical targeted oncogenesis.
Neoplasms
Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis.
Neoplasms
Intramammary lipopolysaccharide infusion alters gene expression but does not induce lysis of the bovine corpus luteum.
Neoplasms
Lipopolysaccharides, cytokines, and nitric oxide affect secretion of prostaglandins and leukotrienes by bovine mammary gland epithelial cells.
Neoplasms
Selective inhibition of human type-5 17?-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Obesity
Depressed Levels of Prostaglandin F2? in Mice Lacking Akr1b7 Increase Basal Adiposity and Predispose to Diet-Induced Obesity.
Obstetric Labor, Premature
Expression of the prostaglandin F synthase AKR1B1 and the prostaglandin transporter SLCO2A1 in human fetal membranes in relation to spontaneous term and preterm labor.
Obstetric Labor, Premature
Increase in prostaglandin H synthase 2, but not prostaglandin F2alpha synthase mRNA in intrauterine tissues during betamethasone-induced premature labor and spontaneous term labor in sheep.
Odontogenic Cysts
Odontogenic cyst growth and prostaglandin-induced bone resorption.
prostaglandin-f synthase deficiency
ER stress-induced adipocytes secrete-aldo-keto reductase 1B7-containing exosomes that cause nonalcoholic steatohepatitis in mice.
Pyometra
Identifying diagnostic endocrine markers and changes in endometrial gene expressions during pyometra in cats.
Pyometra
Prostaglandin synthesis genes are differentially transcripted in normal and pyometra endometria of bitches.
Radicular Cyst
Odontogenic cyst growth and prostaglandin-induced bone resorption.
Venous Thromboembolism
Long-term follow-up of prophylactic greenfield filters in multisystem trauma patients.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.005 - 0.06
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
0.3 - 1
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
0.13 - 1
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
0.06 - 1
(5Z)-7-[(1S,4S,5S,6R)-2-methyl-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
0.052
1-(4-aminobenzyl)-5-methoxy-2-methylindoleacetic acid
Homo sapiens
pH 7.0, 37°C
0.00021
2-(1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl )-N-((trifluoromethyl)sulfonyl)acetamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00009
3-(1-(4-chlorobenzoyl)-3-ethyl-5-methoxy-1H-indol-2-yl)-propanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00022
3-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-propanoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.002
4-benzoyl-benzoic acid
Homo sapiens
-
0.0004
4-carboxy-2',4'-dinitrodiphenylamine
Homo sapiens
-
0.011
4-carboxy-2-aminodiphenylamine
Homo sapiens
-
0.0015
4-chloro-N-(4-tolyl)-anthranilic acid
Homo sapiens
-
0.003
4-chloro-N-phenylanthranilic acid
Homo sapiens
-
0.002
4-nitro-N-phenylanthranilic acid
Homo sapiens
-
0.011
5-methyl-N-phenylanthranilic acid
Homo sapiens
-
1.2
aspirin
Homo sapiens
-
0.0023
indomethacin methyl ester
Homo sapiens
pH 7.0, 37°C
0.00039
Mefenamic acid
Homo sapiens
-
0.0078
N-(4-chlorobenzoyl)-melatonin
Homo sapiens
pH 7.0, 37°C
0.77
salicylic acid
Homo sapiens
-
0.002
4-benzoyl-benzoic acid
Homo sapiens
-
0.0004
4-carboxy-2',4'-dinitrodiphenylamine
Homo sapiens
-
0.011
4-carboxy-2-aminodiphenylamine
Homo sapiens
-
0.0015
4-chloro-N-(4-tolyl)-anthranilic acid
Homo sapiens
-
0.003
4-chloro-N-phenylanthranilic acid
Homo sapiens
-
0.002
4-nitro-N-phenylanthranilic acid
Homo sapiens
-
0.011
5-methyl-N-phenylanthranilic acid
Homo sapiens
-
1.2
aspirin
Homo sapiens
-
0.0078
flurbiprofen
Homo sapiens
-
0.0099
Ibuprofen
Homo sapiens
-
0.0023
indomethacin
Homo sapiens
-
0.0007
Meclofenamic acid
Homo sapiens
-
0.00039
Mefenamic acid
Homo sapiens
-
0.0014
naproxen
Homo sapiens
-
0.77
salicylic acid
Homo sapiens
-
0.0034
sulindac
Homo sapiens
-
0.04
Zomepirac
Homo sapiens
-
0.005
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
Homo sapiens
recombinant enzyme, using prostaglandin D2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.006
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
Homo sapiens
recombinant enzyme, using prostaglandin H2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.06
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
Homo sapiens
recombinant enzyme, using prostamide D2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.3
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
recombinant enzyme, using prostaglandin H2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
IC50 about 1 mM, recombinant enzyme, using prostaglandin D2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
IC50 about 1 mM, recombinant enzyme, using prostamide D2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.13
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
recombinant enzyme, using prostaglandin H2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
IC50 about 1 mM, recombinant enzyme, using prostaglandin D2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
IC50 about 1 mM, recombinant enzyme, using prostamide D2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.06
(5Z)-7-[(1S,4S,5S,6R)-2-methyl-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
recombinant enzyme, using prostaglandin H2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
(5Z)-7-[(1S,4S,5S,6R)-2-methyl-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
IC50 about 1 mM, recombinant enzyme, using prostaglandin D2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
(5Z)-7-[(1S,4S,5S,6R)-2-methyl-6-[(1E)-oct-1-en-1-yl]-2-azabicyclo[2.2.1]hept-5-yl]hept-5-enoic acid
Homo sapiens
IC50 about 1 mM, recombinant enzyme, using prostamide D2 as substrate, in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.005
bimatoprost
Homo sapiens
recombinant enzyme, using prostaglandin D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.006
bimatoprost
Homo sapiens
recombinant enzyme, using prostaglandin H2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.06
bimatoprost
Homo sapiens
recombinant enzyme, using prostamide D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.0078
flurbiprofen
Homo sapiens
-
0.0078
flurbiprofen
Homo sapiens
pH 7.0, 37°C
0.0099
Ibuprofen
Homo sapiens
-
0.0099
Ibuprofen
Homo sapiens
pH 7.0, 37°C
0.0023
indomethacin
Homo sapiens
-
0.0023
indomethacin
Homo sapiens
pH 7.0, 37°C
0.0007
Meclofenamic acid
Homo sapiens
-
0.0007
Meclofenamic acid
Homo sapiens
pH 7.0, 37°C
0.0014
naproxen
Homo sapiens
-
0.0014
naproxen
Homo sapiens
pH 7.0, 37°C
0.13
ONO1349
Homo sapiens
recombinant enzyme, using prostaglandin H2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
ONO1349
Homo sapiens
recombinant enzyme, using prostaglandin D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
ONO1349
Homo sapiens
recombinant enzyme, using prostamide D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.3
ONO1370
Homo sapiens
recombinant enzyme, using prostaglandin H2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
ONO1370
Homo sapiens
recombinant enzyme, using prostaglandin D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
ONO1370
Homo sapiens
recombinant enzyme, using prostamide D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.06
ONO1373
Homo sapiens
recombinant enzyme, using prostaglandin H2 2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
ONO1373
Homo sapiens
recombinant enzyme, using prostaglandin D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
1
ONO1373
Homo sapiens
recombinant enzyme, using prostamide D2 2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.0034
sulindac
Homo sapiens
-
0.0034
sulindac
Homo sapiens
pH 7.0, 37°C
0.1
Tolrestat
Homo sapiens
recombinant enzyme, using prostaglandin D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.3
Tolrestat
Homo sapiens
recombinant enzyme, using prostaglandin H2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.45
Tolrestat
Homo sapiens
recombinant enzyme, using prostamide D2 as substrate,in 0.1 M potassium phosphate buffer, pH 6.5, at 37°C
0.04
Zomepirac
Homo sapiens
-
0.04
Zomepirac
Homo sapiens
pH 7.0, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
evolution
the enzyme belongs to the aldo-keto reductase family 1
metabolism
AKR1C3 is an enzyme responsible for the metabolism of steroid hormones such as androgens, progesterones and estrogens in addition to the reduction of PGD2 to 11beta-PGF2alpha
malfunction
administration of an AKR1C3 inhibitor significantly decreases 11beta-PGF2alpha concentrations in culture media of breast cancer cells
malfunction
although attenuating AKR1C3 expression in squamous cell carcinoma cells by siRNA does not affect growth, treatment with PGD2 and its dehydration metabolite, 15delta-PGJ2, decreases squamous cell carcinoma, SCC, proliferation in a PPARgamma-dependent manner. In addition, treatment with the PPARgamma agonist pioglitazone profoundly inhibits squamous cell carcinoma proliferation. SCC-AKR1C3 metabolizes protaglandin D2, PGD2, to 9alpha,11beta-prostaglandin F2 12fold faster than the parent cell line and is protected from the antiproliferative effect mediated by PGD2. PGD2 and its metabolite 15delta-prostaglandin J2 attenuate SCC proliferation in a PPARgamma-dependent manner, therefore activation of PPARgamma by agonists such as pioglitazone may benefit those at high risk of SCC
malfunction
the enzyme inhibitor 15-deoxy-delta12,14-prostaglandin J2 attenuates proliferation, inhibits collagen gel contraction and induces activation of the apoptotic marker, caspase-3, in CRL1762 keloid fibroblasts, overview
physiological function
AKR1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. AKR1C3 is overexpressed in various malignancies, suggesting a tumor promoting function. SCC-AKR1C3 metabolizes protaglandin D2, PGD2, to 9alpha,11beta prostaglandin F2. Unlike other AKR1C members, AKR1C3 can synthesize prostaglandin F2alpha from prostaglandin H2, an arachidonic acid derivative synthesized by cyclooxygenase
physiological function
in breast cancer, the status of the 11alpha-PGF2alpha and 11beta-PGF2alpha cognate FP receptor is associated with adverse clinical outcome only in the AKR1C3 positive cases, immunohistochemical analysis. FP receptor-mediated functions of 11beta-PGF2alpha using FP receptor expressed MCF-7 cell line shows that 11beta-PGF2alpha treatment phosphorylates ERK and CREB and induces Slug expression through FP receptor in MCF-FP, and MCF-FP cells demonstrate decreased chemosensitivity compared to parental controls. The actions of AKR1C3, but not of AKR1B1, can produce FP receptor ligands whose activation results in carcinoma cell survival in breast cancer. 11beta-PGF2alpha stimulates phosphorylation of ERK and CREB via FP receptor. AKR1C3-dependent signaling performs through 11beta-PGF2alpha and the FP receptor, overview
physiological function
the enzyme is involved in prostaglandins metabolism. The produced PGF2alpha can not only promote prostate cancer cell's proliferation but also enhance prostate cancer cells resistance to radition. Overexpression of AKR1C3 significantly enhances human prostate cancer cells PCa resistance to radiation (or tert-butyl hydroperoxide) through activation of MAPK pathway. AKR1C3 has a pivotal role in the radioresistance of esophageal cancer and non-small-cell lung cancer
physiological function
The major eicosanoid secreted by mast cells is prostaglandin D2 (PGD2), a relatively unstable pro-inflammatory mediator which can be spontaneously converted to 15-deoxy-(Delta12,14)-prostaglandin J2(15d-PGJ2) or enzymatically metabolized to 9alpha,11beta-PGF2 by aldo-keto reductase 1C3 (AKR1C3). Role of enzyme AKR1C3-mediated prostaglandin D2 (PGD2) metabolism in keloids, overview. Keloids are progressively expanding scars, mostly prevalent in individuals of African descent. Metabolism of PGD2 to 9a,11b-PGF2 by both, keloids and normal fibroblasts, is dependent on AKR1C3
evolution
most prostaglandin F2alpha synthases (PGFS) identified to date are aldo-ketoreductases, AKRs
evolution
the enzyme belongs to the aldo-keto reductase family 1
metabolism
AKR1B1 is involved in the synthesis of PGF2alpha. Pathways of prostaglandin F2alpha biosynthesis in human cells, overview
metabolism
AKR1C3 is able to produce PGF2alpha in the endometrium in addition to AKR1B1. The PGF synthase activity of AKR1B1 proves to be much higher than that of AKR1C3
metabolism
there are three different pathways for the synthesis of the uterotonic PGF2alpha: 1. from PGH2 by PGH 9-,11-endoperoxide reductase, 2. from PGD2 by PGD 11-ketoreductase, 3. from PGE2 by PGE 9-ketoreductase
physiological function
in breast cancer, the status of the 11alpha-PGF2alpha and 11beta-PGF2alpha cognate FP receptor is associated with adverse clinical outcome only in the AKR1C3 positive cases, while there are no significant correlations between FP receptor status and any of the clinicathological parameters in AKR1B1 positive cases. AKR1B1 does not induce Slug expression
physiological function
PGF2alpha plays important roles in the regulation of ocular pressure, renal absorption, cardiovascular function, adipocyte differentiation, and female reproductive function. Role of AKR1C3 in the formation of PGF2alpha from PGH2 in the bovine endometrium
physiological function
prostaglandins (PGs) are important regulators of female reproductive function. The primary PGs produced in the endometrium are PGE2 and PGF2alpha. Role of aldo-ketoreductase (AKR)1B1 in increased PGF2alpha production by human endometrial cells following stimulation with interleukin-1beta (IL-1beta)
additional information
comparisons of PGFS activity of recombinant bovine and human endometrial AKRs, overview
additional information
-
comparisons of PGFS activity of recombinant bovine and human endometrial AKRs, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Suzuki-Yamamoto, T.; Nishizawa, M.; Fukui, M.; Okuda-Ashitaka, E.; Nakajima, T.; Ito, S.; Watanabe, K.
cDNA cloning, expression and characterization of human prostaglandin F synthase
FEBS Lett.
462
335-340
1999
Homo sapiens
brenda
Wolfe, L.S.; Rostworowski, K.; Pellerin, L.; Sherwin, A.
Metabolism of prostaglandin D2 by human cerebral cortex into 9alpha,11beta-prostaglandin F2 by an active NADPH-dependent 11-ketoreductase:Metabolism of prostaglandin D2 by human cerebral cortex into 9alpha,11beta-prostaglandin F2 by an active NADPH-dependent 11-ketoreductase
J. Neurochem.
53
64-70
1989
Homo sapiens
brenda
Koda, N.; Tsutsui, Y.; Niwa, H.; Ito, S.; Woodward, D.F.; Watanabe, K.
Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS
Arch. Biochem. Biophys.
424
128-136
2004
Homo sapiens, Homo sapiens (P42330)
brenda
Komoto, J.; Yamada, T.; Watanabe, K.; Takusagawa, F.
Crystal structure of human prostaglandin F synthase (AKR1C3)
Biochemistry
43
2188-2198
2004
Homo sapiens (P42330), Homo sapiens
brenda
Nakashima, K.; Ueno, N.; Kamei, D.; Tanioka, T.; Nakatani, Y.; Murakami, M.; Kudo, I.
Coupling between cyclooxygenases and prostaglandin F(2alpha) synthase. Detection of an inducible, glutathione-activated, membrane-bound prostaglandin F2alpha-synthetic activity
Biochim. Biophys. Acta
1633
96-105
2003
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Lovering, A.L.; Ride, J.P.; Bunce, C.M.; Desmond, J.C.; Cummings, S.M.; White, S.A.
Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin
Cancer Res.
64
1802-1810
2004
Homo sapiens (P42330)
brenda
Watanabe, K.
Prostaglandin F synthase
Prostaglandins
68-69
401-407
2002
Bos taurus, Oryctolagus cuniculus, Ovis aries, Homo sapiens, Rattus norvegicus, Trypanosoma brucei
brenda
Sakurai, M.; Oishi, K.; Watanabe, K.
Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma
Biochem. Biophys. Res. Commun.
338
82-86
2005
Homo sapiens
brenda
Komoto, J.; Yamada, T.; Watanabe, K.; Woodward, D.F.; Takusagawa, F.
Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost
Biochemistry
45
1987-1996
2006
Homo sapiens, Homo sapiens (P42330)
brenda
Yang, W.; Ni, J.; Woodward, D.F.; Tang-Liu, D.D.; Ling, K.H.
Enzymatic formation of prostamide F2alpha from anandamide involves a newly identified intermediate metabolite, prostamide H2
J. Lipid Res.
46
2745-2751
2005
Homo sapiens
brenda
Byrns, M.C.; Steckelbroeck, S.; Penning, T.M.
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies
Biochem. Pharmacol.
75
484-493
2008
Homo sapiens (P42330)
brenda
Dozier, B.L.; Watanabe, K.; Duffy, D.M.
Two pathways for prostaglandin F2 alpha synthesis by the primate periovulatory follicle
Reproduction
136
53-63
2008
Homo sapiens (P42330), Homo sapiens AKR1C3 (P42330), Macaca fascicularis, Macaca fascicularis AKR1C3
brenda
Byrns, M.; Penning, T.
Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): Role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs
Chem. Biol. Interact.
178
221-227
2009
Homo sapiens, Homo sapiens (P42330)
brenda
Inagaki, S.; Esaka, Y.; Deyashiki, Y.; Uno, B.; Hara, A.; Toyooka, T.
Human liver dihydrodiol dehydrogenase 1-catalyzed reaction generating 9alpha,11beta-prostaglandin F2 from prostaglandin D2 followed by micellar electrokinetic chromatography
J. Sep. Sci.
31
735-740
2008
Homo sapiens
brenda
Kabututu, Z.; Manin, M.; Pointud, J.C.; Maruyama, T.; Nagata, N.; Lambert, S.; Lefrancois-Martinez, A.M.; Martinez, A.; Urade, Y.
Prostaglandin F2alpha synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7
J. Biochem.
145
161-168
2009
Homo sapiens (P15121), Homo sapiens (P42330), Homo sapiens, Mus musculus
brenda
Phillips, R.J.; Al-Zamil, H.; Hunt, L.P.; Fortier, M.A.; Lopez Bernal, A.
Genes for prostaglandin synthesis, transport and inactivation are differentially expressed in human uterine tissues, and the prostaglandin F synthase AKR1B1 is induced in myometrial cells by inflammatory cytokines
Mol. Hum. Reprod.
17
1-13
2011
Homo sapiens
brenda
Nagata, N.; Kusakari, Y.; Fukunishi, Y.; Inoue, T.; Urade, Y.
Catalytic mechanism of the primary human prostaglandin F2alpha synthase, aldo-keto reductase 1B1 - prostaglandin D2 synthase activity in the absence of NADP(H)
FEBS J.
278
1288-1298
2011
Homo sapiens (P15121), Homo sapiens, Mus musculus
brenda
Bresson, E.; Lacroix-Pepin, N.; Boucher-Kovalik, S.; Chapdelaine, P.; Fortier, M.A.
The prostaglandin F synthase activity of the human aldose reductase AKR1B1 brings new lenses to look at pathologic conditions
Front. Pharmacol.
3
98
2012
Homo sapiens (P15121), Homo sapiens
brenda
Bresson, E.; Boucher-Kovalik, S.; Chapdelaine, P.; Madore, E.; Harvey, N.; Laberge, P.Y.; Leboeuf, M.; Fortier, M.A.
The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium
J. Clin. Endocrinol. Metab.
96
210-219
2011
Homo sapiens (P15121), Homo sapiens
brenda
Liedtke, A.J.; Adeniji, A.O.; Chen, M.; Byrns, M.C.; Jin, Y.; Christianson, D.W.; Marnett, L.J.; Penning, T.M.
Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer
J. Med. Chem.
56
2429-2446
2013
Homo sapiens (P42330)
brenda
Mantel, A.; Carpenter-Mendini, A.; VanBuskirk, J.; Pentland, A.P.
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism
Exp. Dermatol.
23
573-578
2014
Homo sapiens (P42330)
brenda
Mantel, A.; Newsome, A.; Thekkudan, T.; Frazier, R.; Katdare, M.
The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids
Exp. Dermatol.
25
38-43
2016
Homo sapiens (P42330)
brenda
Alzamil, H.A.; Pawade, J.; Fortier, M.A.; Bernal, A.L.
Expression of the prostaglandin F synthase AKR1B1 and the prostaglandin transporter SLCO2A1 in human fetal membranes in relation to spontaneous term and preterm labor
Front. Physiol.
5
272
2014
Homo sapiens (P15121), Homo sapiens
brenda
Yoda, T.; Kikuchi, K.; Miki, Y.; Onodera, Y.; Hata, S.; Takagi, K.; Nakamura, Y.; Hirakawa, H.; Ishida, T.; Suzuki, T.; Ohuchi, N.; Sasano, H.; McNamara, K.M.
11beta-Prostaglandin F2alpha, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer
Mol. Cell. Endocrinol.
413
236-247
2015
Homo sapiens (P15121), Homo sapiens (P42330)
brenda
Lacroix Pepin, N.; Chapdelaine, P.; Rodriguez, Y.; Tremblay, J.P.; Fortier, M.A.
Generation of human endometrial knockout cell lines with the CRISPR/Cas9 system confirms the prostaglandin F2alpha synthase activity of aldo-ketoreductase 1B1
Mol. Hum. Reprod.
20
650-663
2014
Homo sapiens (P15121), Homo sapiens
brenda
Sun, S.Q.; Gu, X.; Gao, X.S.; Li, Y.; Yu, H.; Xiong, W.; Yu, H.; Wang, W.; Li, Y.; Teng, Y.; Zhou, D.
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation
Oncotarget
7
48050-48058
2016
Homo sapiens (P42330)
brenda
Lacroix Pepin, N.; Chapdelaine, P.; Fortier, M.A.
Evaluation of the prostaglandin F synthase activity of human and bovine aldo-keto reductases: AKR1A1s complement AKR1B1s as potent PGF synthases
Prostaglandins Other Lipid Mediat.
106
124-132
2013
Bos taurus (P16116), Bos taurus, Homo sapiens (P15121), Homo sapiens
brenda